Novo Nordisk A/S: Monlunabant phase 2a trial in obesity …
WEB1 day ago · Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse ...
Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players
WEB1 day ago · Earlier on Friday, Novo Nordisk A/S (NYSE:NVO) announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral cannabinoid receptor 1 (CB1) inverse agonist. After ...
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity
WEB1 day ago · Monlunabant is an inverse agonist of the CB1 receptor which plays an important role in metabolism and appetite regulation in the central nervous system as well as in peripheral tissues such as ...
Monlunabant phase 2a trial in obesity successfully completed
WEBNews & Events. Latest releases; Monlunabant phase 2a trial in obesity successfully completed. Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV …
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity …
WEB1 day ago · Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc. announced in August 2023 [Link].The trial investigated the efficacy and safety of a once-daily 10 ...
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity …
WEB1 day ago · The trial investigated the efficacy and safety of a once-daily 10 mg, 20 mg and 50 mg dose of monlunabant compared to placebo on body weight after 16 weeks in 243 people with obesity and metabolic ...
Novo Nordisk’s obesity newcomer monlunabant heads into …
WEB1 day ago · Novo Nordisk has now announced headline results from a Phase IIa trial with monlunabant investigating the efficacy and safety of a once-daily 10 mg, 20 mg and 50 mg dose compared to placebo on body weight after 16 weeks in 243 people with obesity and metabolic syndrome. People were equally randomized among the four treatment arms.
Novo’s Next-Gen CB1 Drug Leads to Weight Loss in Phase II, but ...
WEB1 day ago · The trial examined three doses of monlunabant in 243 patients, and the average weight loss of 15 lbs was achieved in the lowest dose arm, where patients received 10 mg. Novo said that “limited additional weight loss was seen at higher doses of monlunabant.” ... BioSpace is the digital hub for life science news and …
Novo Nordisk Stock Declines After Headline Results From Mid …
WEB1 day ago · Friday, Novo Nordisk A/S (NYSE:NVO) announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant ...
Novo Nordisk Slips On Phase 2a Clinical Trial Result With Monlunabant
WEB1 day ago · Friday, shares of Novo Nordisk A/S are sliding following the announcement of safety results of phase 2a clinical trial of Monlunabant compared to placebo in patients with obesity and metabolic syndrome.Monlunabant, formerly INV-202, is a small molecule oral cannabinoid receptor 1 or CB1 inverse agonist. The trial investigated efficacy and safety, and post 16 weeks, people treated with a once ...
- Some results have been removed